Search clinical trials for: Sodium Zirconium Cyclosilicate (ZS) 10g

Total 668 results

AstraZeneca

Completed

A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia (HARMONIZE GL)

Hyperkalemia

Korea, Republic of, Taiwan, Russian Federation, Japan
AstraZeneca

Completed

ZS Ph2/3 Dose-response Study in Japan

Hyperkalemia

Japan
ZS Pharma, Inc.

Completed

Open-label Safety & Efficacy of ZS (Sodium Zirconium Cyclosilicate)10g qd to Extend Study ZS-004 in Hyperkalemia.

Hyperkalemia

United States, South Africa, Australia
AstraZeneca

Completed

A Safety and Pharmacodynamic Study of Healthy Chinese Subjects Administered Sodium Zirconium Cyclosilicate (ZS)

Hyperkalemia

Hong Kong
ZS Pharma, Inc.

Completed

Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months

Hyperkalemia

United States, Germany, Australia, Netherlands, South Africa, Romania, United Kingdom
AstraZeneca

Completed

A Study to Test Whether ZS (Sodium Zirconium Cyclosilicate) Can Reduce the Incidence of Increased Blood Potassium Levels Among Dialized Patients. (DIALIZE)

Hyperkalemia

United States, United Kingdom, Russian Federation, Japan
AstraZeneca

Completed

Open-label Safety of Sodium Zirconium Cyclosilicate for up to 12 Months in Japanese Subjects With Hyperkalemia

Hyperkalemia

Japan
AstraZeneca

Completed

Reduce Incidence of Pre-Dialysis Hyperkalaemia With Sodium Zirconium Cyclosilicate in Chinese Subjects (DIALIZE China)

Hyperkalemia

China
AstraZeneca

Terminated

Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure (PRIORITIZE HF)

Heart Failure

United States, Canada, Brazil, Slovakia, Hungary, Romania, Poland, Russian Federation, Bulgaria
AstraZeneca

Completed

A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia. (HARMONIZE Asia)

Hyperkalemia

China
ZS Pharma, Inc.

Completed

Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia.

Hyperkalemia

United States, South Africa, Australia
AstraZeneca

Completed

A Study to Evaluate a Potassium Normalization Treatment Regimen Including Sodium Zirconium Cyclosilicate (ZS) Among Patients With S-K ≥5.8 (ENERGIZE)

Hyperkalemia

United States, Russian Federation, Italy, Denmark
Barts & The London NHS Trust

Terminated

The ORTIZ Study: Optimising RASi Therapy With SZC (ORTIZ)

Diabetes Mellitus, Type 2 | CKD | Hyperkalemia

United Kingdom
Guangdong Provincial People's Hospital

Completed

Sodium Zirconium Cyclosilicate Lowers Hyperkalemia After Parathyroidectomy (SZC)

Hyperparathyroidism, Secondary | Hyperkalemia | Sodium Zirconium Cyclosilicate
Leiden University Medical Center
AstraZeneca

Not yet recruiting

Sodium Zirconium Cyclosilicate to Allow Liberal Fruit and Vegetable Intake for Patients With CKD Stage 3b and 4 (LIBRAL)

Diet Modification | Chronic Kidney Disease | Hyperkalemia | Sodium Zirconium Cyclosilicate
AstraZeneca

Recruiting

An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia (PEDZ-K)

Hyperkalaemia

China, Germany, United States, Ukraine, Spain, Japan, United Kingdom, Canada, Poland, Romania, Russian Federation, Brazil
Brigham and Women's Hospital

Unknown

Potassium Binder in CKD Patients (With Hyperkalemia) (DiPo Trial)

Chronic Kidney Diseases | Hyperkalemia

United States
Karolinska Institutet
AstraZeneca

Completed

Healthy Diet Rich in Potassium to Chronic Kidney Disease With Sodium Zirconium Cyclosilicate: A Feasibility Study (HELPFUL)

Chronic Kidney Disease Stage 5 | Hyperkalemia | Chronic Kidney Disease stage4

Sweden
AstraZeneca

Terminated

Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)

Hyperkalemia

United States, Italy, Spain, Taiwan, Thailand, Vietnam, Russian Federation, Canada, Hungary, Mexico, China, Austria, Turkey, Brazil, Germany, Poland, Czechia, United Kingdom, Bulgaria, Slovakia, Peru, Ukraine, Japan, Argentina, Malaysia, ...
ZS Pharma, Inc.

Completed

Safety & Efficacy of Zirconium Silicate in Chronic Kidney Disease or Moderate Kidney Dysfunction With Mild Hyperkalemia

Chronic Kidney Disease | Hyperkalemia | Kidney Dysfunction

United States
AstraZeneca

Recruiting

Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge Study (CONTINUITY)

Chronic Kidney Disease | Hyperkalaemia

United Kingdom, Spain, Belgium, Italy, Netherlands, France, Germany
AstraZeneca

Recruiting

A National, Multicenter, Prospective, Observational Study to Assess Patient Characteristics, Treatment Algorithms and Disease Management of Hyperkalaemia Patients With Chronic Kidney Disease or Under Dialysis or With Heart Failure, Treated With Sodium Zirconium Cyclosilicate in Greece (SHIELD)

Hyperkalaemia

Greece
Michael Fu
Göteborg University; AstraZeneca

Recruiting

OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart Failure (OPRA-HF)

Heart Failure | Hyperkalemia

Sweden
AstraZeneca

Terminated

Study of the Effect of SZC on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney Disease (NEUTRALIZE)

Chronic Kidney Disease | Metabolic Acidosis | Hyperkalaemia

United States, Puerto Rico
ZS Pharma, Inc.

Completed

Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia

Hyperkalemia

United States, Australia
Alexandria University

Recruiting

SZC Versus SPS for Treatment of Hyperkalemia in Hemodialysis Patients

Hyperkalemia

Egypt
AstraZeneca

Terminated

Study of SZC and Enhanced Nutrition Advice Compared to SoC in Dialysis Patients With Hyperkalaemia (GRAZE)

Hyperkalaemia

United States
Peking University First Hospital

Recruiting

The Effect of Potassium Lowering Drugs on Cardiac Electrical Stability in Hemodialysis Patients (ART Study)

Cardiac Arrhythmia | Potassium Imbalance | Dialysis; Complications

China
University of California, Irvine

Recruiting

Comparison of Potassium Binders in the ER (KBindER)

Acute Hyperkalemia | Oral Potassium Binders

United States
AstraZeneca

Active, not recruiting

Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone (REALIZE-K)

Heart Failure With Reduced Ejection Fraction | Hyperkalaemia

United States, Spain, Canada, Brazil, Hungary, Czechia, Ukraine, Poland, United Kingdom
AstraZeneca
Parexel

Completed

Study to Assess the Effect of Sodium Zirconium Cyclosilicate on the Pharmacokinetics of Tacrolimus and Cyclosporin in Healthy Subjects

Hyperkalaemia

Germany
AstraZeneca

Terminated

A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia (STABILIZE-CKD)

Renal Insufficiency, Chronic | Hyperkalemia

United States, Italy, Spain, Thailand, Vietnam, Turkey, Canada, Philippines, China, Malaysia, Taiwan, Brazil, Japan, Bulgaria, Russian Federation, Poland, Argentina, Mexico, Ukraine, India, Puerto Rico
UCB Pharma SA
UCB Japan Co. Ltd.

Completed

A Trial to Evaluate the Efficacy and Safety of Adjunctive Therapy With Lacosamide in Adults With Partial-Onset Seizures

Epilepsy | Partial Onset Seizures

China, Japan
University of Colorado, Denver
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes (MANATEE-T1D)

Cardiovascular Diseases | Type 1 Diabetes | Diabetic Kidney Disease | Endothelial Dysfunction | Insulin Sensitivity

United States
University of Michigan
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Sodium Diet Effect on Aldosterone and Urinary RNA (SALTY) (SALTY)

Healthy

United States
Hope Pharmaceuticals
National Institute of Neurological Disorders and Stroke (NINDS)

Completed

Safety and Pharmacokinetic Evaluation of Nitrite for Prevention of Cerebral Vasospasm

Subarachnoid Hemorrhage

United States
University Hospital, Basel, Switzerland

Completed

Oral Glucosestimulation After Gastric Bypass Surgery

Obesity

Switzerland
Takeda
COUR Pharmaceuticals Development Company, Inc.

Completed

Study of the Safety, Pharmacodynamics, Efficacy, and PK of TIMP-GLIA in Subjects With Celiac Disease

Celiac Disease

United States
Aditya Kaza
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Utilization of Confocal Microscopy During Cardiac Surgery

Atrial Septal Defect

United States
Hope Pharmaceuticals

Terminated

Intravenous Nitrite Infusion for Reversal of Cerebral Vasospasm After Subarachnoid Hemorrhage

Subarachnoid Hemorrhage

United States
Pyramid Biosciences

Completed

A Study to Evaluate the Skin Irritation Potential of PBI-100 Topical Cream in Healthy Participants

Healthy Volunteers

United States
Ayman Anis Metry

Completed

Hypophosphatemia Deleteriously Affects Outcome of Septic Shock Patients Admitted to ICU

Effect of Hypophosphatemia on Septic Patients

Egypt
Yeditepe University

Completed

Pain Relief During Intravenous Cannulation in Pediatric Patients

Local Anesthesia | Cannula Site Pain

Turkey
Sadat City University

Recruiting

Assessment of Empagliflozin as Adjuvant Therapy in Patients With Ulcerative Colitis

Ulcerative Colitis

Egypt
MediBeacon

Not yet recruiting

Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium

Macular Degeneration | Diabetic Retinopathy | Retinal Vein Occlusion | Retinopathy

United States
TScan Therapeutics, Inc.

Recruiting

A Study of TSC-100 and TSC-101 in AML, ALL and MDS Patients Undergoing Haploidentical Donor Transplantation

Myelodysplastic Syndromes | AML | ALL, Adult

United States
Zeria Pharmaceutical

Completed

To Evaluate Pharmacokinetics and Pharmacodynamics of Z-215 in Healthy Male Subjects

Healthy

Japan
Sun Yat-sen University

Completed

Whitening Efficacy of Dentifrice Containing 10% High Cleaning Silica, 0.5% Sodium Phytate and 0.5% Sodium Pyrophosphate

Tooth Bleaching

China
Hookipa Biotech GmbH
Centre for Vaccinology Ghent - CEVAC

Completed

Trial to Evaluate Safety and Immunogenicity of a Vaccine Against HCMV

Cytomegalovirus Infection

Belgium
Rigel Pharmaceuticals

No longer available

Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP

Immune Thrombocytopenic Purpura

3

Subscribe